Drug
Pegcetacoplan
Pegcetacoplan: highest development phase Post-Market, developed by Apellis Pharmaceuticals, Swedish Orphan Biovitrum. 19 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Apellis Pharmaceuticals, Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pegcetacoplan NCT07746895 | Post-Market | C3 Glomerulopathy (C3G) |
| Pegcetacoplan NCT05067127 | Phase 3 | C3G |
| Pegcetacoplan NCT05809531 | Phase 3 | C3G |
| Pegcetacoplan NCT03531255 | Phase 3 | PNH |
| Pegcetacoplan NCT07020832 | Phase 3 | Delayed Graft Function |
| Pegcetacoplan NCT07898774 | Phase 3 | C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) |
| Pegcetacoplan NCT03500549 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| PEGCETACOPLAN (APL-2) NCT04770545 | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| Pegcetacoplan NCT03593200 | Phase 2 | PNH |
| Pegcetacoplan NCT02503332 | Phase 2 | Geographic Atrophy |
| Pegcetacoplan NCT05148299 | Phase 2 | Transplant-Associated Thrombotic Microangiopathy |
| Pegcetacoplan NCT04901936 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Pegcetacoplan (APL-2) NCT04579666 | Phase 2 | Amyotrophic Lateral Sclerosis |
| Pegcetacoplan NCT04572854 | Phase 2 | C3G |
| Pegcetacoplan NCT03465709 | Phase 1/2 | Neovascular Age-related Macular Degeneration |
| Pegcetacoplan NCT02461771 | Phase 1 | Neovascular Age-Related Macular Degeneration |
| Pegcetacoplan NCT02588833 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria |
| PEGCETACOPLAN (APL-2) NCT03777332 | Phase 1 | Geographic Atrophy |
| Pegcetacoplan NCT02264639 | Phase 1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Latest
No recent events.
Follow Pegcetacoplan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.